检索结果 - Roger von Moos
- Showing 1 - 20 results of 35
- Go to Next Page
-
1
-
2
-
3
-
4
-
5
-
6
A cost-effectiveness analysis of sotorasib as second-line treatment for patients with KRAS-G12C-mutated metastatic non-small cell lung cancer (mNSCLC) in Switzerland 由 Tämer El Saadany, Judith E. Lupatsch, Michael Mark, Michaela Barbier, Tarun Mehra, Matthias Schwenkglenks, Roger von Moos
出版 2025Artigo -
7
-
8
A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing 由 Klazien Matter‐Walstra, Matthias Schwenkglenks, Stefan Aebi, Konstantin J. Dedes, Joachim Diebold, Mario Pietrini, Dirk Klingbiel, Roger von Moos, Oliver Gautschi
出版 2016Artigo -
9
Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours 由 Gianluca Del Conte, Cristiana Sessa, Roger von Moos, Lucia Viganò, Tiziana Digena, Alberta Locatelli, Elisa Gallerani, Angelica Fasolo, Anna Tessari, Richard Cathomas, Luca Gianni
出版 2014Artigo -
10
Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study 由 Florian Strasser, Thomas A. Lutz, Micha T. Maeder, B. Thuerlimann, Doug Bueche, M. Tschöp, K. Kaufmann, Birgitte Holst, Michael Brändle, Roger von Moos, Ruth Demmer, T. Cerny
出版 2008Artigo -
11
Encorafenib (Lgx818), an Oral Braf Inhibitor, in Patients (Pts) with Braf V600E Metastatic Colorectal Cancer (Mcrc): Results of Dose Expansion in an Open-Label, Phase 1 Study 由 Carlos Gomez‐Roca, Jean‐Pierre Delord, Caroline Robert, Manuel Hidalgo, Roger von Moos, Ana Arance, Elena Élez, Daniela Michel, Abdelkader Seroutou, Tim Demuth, Josep Tabernero
出版 2014Artigo -
12
Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer 由 Dieter Koeberle, Roger Burkhard, Roger von Moos, Sun Young Rha, Viviane Hess, F. Heitzmann, Thomas Ruhstaller, L. Terraciano, J. Neuweiler, G. Bieri, C Rust, M. Toepfer
出版 2008Artigo -
13
The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma 由 Reinhard Dummer, Marco Siano, Robert E. Hunger, Nicole Lindenblatt, Ralph P. Braun, Olivier Michielin, Daniela Mihic‐Probst, Roger von Moos, Yousef Najafi, Matthias Gückenberger, Andreas Arnold
出版 2016Revisão -
14
-
15
The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MO AIC, a multicenter cluster-ran... 由 Florian Strasser, David Blum, Roger von Moos, Richard Cathomas, Karin Ribi, Stefan Aebi, Daniel Betticher, Stefanie Hayoz, Dirk Klingbiel, Peter Brauchli, Michael Haefner, Silvia Mauri, S. Kaasa, Dieter Koeberle
出版 2015Artigo -
16
Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tu... 由 David H. Henry, Saroj Vadhan‐Raj, Vera Hirsh, Roger von Moos, Vânia Hungria, Luís Costa, Penella J. Woll, Giorgio V. Scagliotti, Geoffrey Smith, Amy Feng, Susie Jun, Roger Dansey, Howard Yeh
出版 2013Artigo -
17
Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid 由 Saroj Vadhan‐Raj, Roger von Moos, Lesley Fallowfield, Donald L. Patrick, François Goldwasser, Charles S. Cleeland, David H. Henry, Silvia Novello, Vânia Hungria, Yi Qian, A. Feng, Hong‐Zen Yeh, Karen Chung
出版 2012Artigo -
18
Cetuximab in Combination With Chemoradiotherapy Before Surgery in Patients With Resectable, Locally Advanced Esophageal Carcinoma: A Prospective, Multicenter Phase IB/II Trial (SAK... 由 Thomas Ruhstaller, Miklos Pless, Daniel Dietrich, Helmut Kranzbuehler, Roger von Moos, Peter Moosmann, Michael Montemurro, Paul M. Schneider, Daniel Rauch, Oliver Gautschi, Walter Mingrone, Lucas Widmer, Roman Inauen, Peter Brauchli, Viviane Hess
出版 2011Artigo -
19
Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02) 由 Thomas Ruhstaller, L. Widmer, Jan C. Schuller, A. Roth, Viviane Hess, Walter Mingrone, Roger von Moos, Markus Borner, Bernhard C. Pestalozzi, Sabine Balmer-Majno, Dieter Köberle, L. Terraciano, Armin Schnider, Stephan Bodis, Răzvan Popescu
出版 2009Artigo -
20
First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07) 由 Roger von Moos, Burkhardt Seifert, Mathew Simcock, Simone M. Goldinger, Silke Gillessen, Adrian F. Ochsenbein, Olivier Michielin, Richard Cathomas, Marc Schläppi, Holger Moch, Peter Schraml, D. Mjhic-Probst, Christoph Mamot, Nicola Schönewolf, Reinhard Dummer
出版 2011Artigo
相关主题
Medicine
Internal medicine
Cancer
Oncology
Chemotherapy
Adverse effect
Surgery
Breast cancer
Cancer research
Colorectal cancer
Phases of clinical research
Denosumab
Gastroenterology
Osteoporosis
Zoledronic acid
Bevacizumab
Chemoradiotherapy
Clinical endpoint
Clinical trial
Environmental health
Melanoma
Population
Prostate cancer
Bone pain
Immunology
Immunotherapy
Multiple myeloma
Radiation therapy
Randomized controlled trial
Biology